MedTrace Logo

A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS

NCT02267863 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2022-08-22

No results posted yet for this study

Summary

This study is being done to evaluate the safety and effectiveness of APTO-253 for the treatment of patients with the condition of acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) for which either the standard treatment has failed, is no longer effective, or can no longer be administered safely or poses a risk for your general well being.

Conditions

  • Acute Myelogenous Leukemia in Relapse
  • Acute Myelogenous Leukemia, Relapsed, Adult
  • Acute Myelogenous Leukemia, Adult
  • Acute Myelogenous Leukemia
  • High Risk Myelodysplasia

Interventions

DRUG

APTO-253

APTO-253 will be given in ascending doses starting at 20 mg/m2 until the maximum tolerated dose or recommended dose is reached.

Sponsors & Collaborators

  • Aptose Biosciences Inc.

    lead INDUSTRY

Principal Investigators

  • Rafael Bejar, MD., PhD. · Aptose Biosciences Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02267863 on ClinicalTrials.gov